Urinary nucleic acid oxidation product levels show differential associations with pharmacological treatment in patients with type 2 diabetes

References

• Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058–1070.
   PubMed Web of Science ®Google Scholar
• Johansen J, Harris AK, Rychly DJ, et al. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol. 2005;4:5.
   PubMed Web of Science ®Google Scholar
• Bjelakovic G, Gluud LL, Simonetti RG, et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2012;3:CD007176.
   PubMed Web of Science ®Google Scholar
• Gæde P, Lund-Andersen H, Parving H-H, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591.
   PubMed Web of Science ®Google Scholar
• Tancredi M, Rosengren A, Svensson A-M, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373:1720–1732.
   PubMed Web of Science ®Google Scholar
• Giorgino F, Home PD, Tuomilehto J. Glucose control and vascular outcomes in type 2 diabetes: is the picture clear? Diabetes Care. 2016;39:S187–S195.
   PubMedGoogle Scholar
• Group F-NBW. BEST (Biomarkers, EndpointS, and other Tools) resource. Silver Spring, MD: Food and Drug Administration; 2016.
   Google Scholar
• Broedbaek K, Siersma V, Henriksen T, et al. Urinary markers of nucleic acid oxidation and long-term mortality of newly diagnosed type 2 diabetic patients. Diabetes Care. 2011;34:2594–2596.
   PubMed Web of Science ®Google Scholar
• Broedbaek K, Siersma V, Henriksen T, et al. Association between urinary markers of nucleic acid oxidation and mortality in type 2 diabetes: a population-based cohort study. Diabetes Care 2013;36:669–676.
   PubMed Web of Science ®Google Scholar
• Kjær LK, Cejvanovic V, Henriksen T, et al. Cardiovascular and all-cause mortality risk associated with urinary excretion of 8-oxoguo, a biomarker for RNA oxidation, in patients with type 2 diabetes: a prospective cohort study. Diabetes Care. 2017;40:1771–1778.
   PubMed Web of Science ®Google Scholar
• Petersen E, Nielsen AA, Christensen H, Hansen T, et al. Vejle Diabetes Biobank – a resource for studies of the etiologies of diabetes and its comorbidities. Clin Epidemol. 2016;8:393–413.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29:541–549.
   PubMed Web of Science ®Google Scholar
• Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39:38–41.
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology, WHOCC. Available from: https://www.whocc.no/
   Google Scholar
• Rasmussen ST, Andersen JT, Nielsen TK, et al. Simvastatin and oxidative stress in humans: a randomized, double-blinded, placebo-controlled clinical trial. Redox Biol. 2016;9:32–38.
   PubMed Web of Science ®Google Scholar
• Weimann A, Broedbaek K, Henriksen T, et al. Assays for urinary biomarkers of oxidatively damaged nucleic acids. Free Radic Res. 2012;46:531–540.
   PubMed Web of Science ®Google Scholar
• Loft S, Svoboda P, Kasai H, et al. Prospective study of 8-oxo-7,8-dihydro-2′-deoxyguanosine excretion and the risk of lung cancer. Carcinogenesis. 2006;27:1245–1250.
   PubMed Web of Science ®Google Scholar
• Liu X, Gan W, Zou Y, et al. Elevated levels of urinary markers of oxidative DNA and RNA damage in Type 2 diabetes with complications. Oxid Med Cell Longev. 2016;2016:1.
   Web of Science ®Google Scholar
• Andreoli R, Mutti A, Goldoni M, et al. Reference ranges of urinary biomarkers of oxidized guanine in (2′-deoxy)ribonucleotides and nucleic acids. Free Radic Biol Med. 2011;50:254–261.
   PubMed Web of Science ®Google Scholar
• Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. Br Med J 1995;310:170.
   PubMed Web of Science ®Google Scholar
• R Foundation for Computing. R Core Team R: a language and environment for statistical computing R Foundation for Statistical. [2017]. Available from: https://www.r-project.org/
   Google Scholar
• Poulsen HE, Specht E, Broedbaek K, et al. RNA modifications by oxidation: a novel disease mechanism? Free Radic Biol Med. 2012;52:1353–1361.
   PubMed Web of Science ®Google Scholar
• Thomas MC, Woodward M, Li Q, et al. Relationship between plasma 8-OH-deoxyguanosine and cardiovascular disease and survival in type 2 diabetes mellitus: results from the ADVANCE trial. J Am Heart Assoc. 2018;7:e008226.
   PubMed Web of Science ®Google Scholar
• Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39:44–84.
   PubMed Web of Science ®Google Scholar
• Ceriello A. New insights on oxidative stress and diabetic complications may lead to a ‘causal’ antioxidant therapy. Diabetes Care. 2003;26:1589–1596.
   PubMed Web of Science ®Google Scholar
• Ceriello A, Testa R. Antioxidant anti-inflammatory treatment in type 2 diabetes. Diabetes Care. 2009;32:S232–S236.
   PubMed Web of Science ®Google Scholar
• Larsen EL, Cejvanovic V, Kjaer LK, et al. Clarithromycin, trimethoprim, and penicillin and oxidative nucleic acid modifications in humans: randomised, controlled trials. Br J Clin Pharmacol. 2017;83:1643–1653.
   PubMed Web of Science ®Google Scholar
• Winkel P, Hilden J, Hansen JF, et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial. Int J Cardiol. 2015;182:459–465.
   PubMed Web of Science ®Google Scholar
• Sørensen AL, Hasselbalch HC, Nielsen CH, et al. Statin treatment, oxidative stress and inflammation in a Danish population. Redox Biol. 2019;21:1–7.
   Web of Science ®Google Scholar
• Broedbaek K, Ribel-Madsen R, Henriksen T, et al. Genetic and environmental influences on oxidative damage assessed in elderly Danish twins. Free Radic Biol Med. 2011;50:1488–1491.
   PubMed Web of Science ®Google Scholar
• Ceriello A, Testa R, Genovese S. Clinical implications of oxidative stress and potential role of natural antioxidants in diabetic vascular complications. Nutr Metab Cardiovasc Dis. 2016;26:285–292.
   PubMed Web of Science ®Google Scholar
• Young AJ, Lowe GL. Carotenoids-antioxidant properties. Antioxid. 2018;7:pii: E28.
   Web of Science ®Google Scholar
• Cefalu WT, Rosenstock J, LeRoith D, et al. Getting to the ‘heart’ of the matter on diabetic cardiovascular disease: “thanks for the memory”. Diabetes Care. 2016;39:664–667.
   PubMed Web of Science ®Google Scholar
• Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712–1719.
   PubMed Web of Science ®Google Scholar
• Sies H, Berndt C, Jones DP. Oxidative stress. Annu Rev Biochem. 2017;86:715–748.
   PubMed Web of Science ®Google Scholar
• Koska J, Saremi A, Howell S, et al. Advanced glycation end products, oxidation products, and incident cardiovascular events in patients with Type 2 diabetes. Diabetes Care. 2018;41:570–576.
   PubMed Web of Science ®Google Scholar
• Kjaer LK, Oellgaard J, Henriksen T, et al. Indicator of RNA oxidation in urine for the prediction of mortality in patients with type 2 diabetes and microalbuminuria: a post-hoc analysis of the Steno-2 trial. Free Radic Biol Med. 2018;129:247–255.
   PubMed Web of Science ®Google Scholar
• Ferrante JM, Ohman-Strickland P, Hahn KA, et al. Self-report versus medical records for assessing cancer-preventive services delivery. Cancer Epidemiol Biomarkers Prev. 2008;17:2987–2994.
   PubMed Web of Science ®Google Scholar
• Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, et al. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46:798–798.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• Larsen EL, Cejvanovic V, Kjær LK, et al. The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial. BMJ Open. 2017;7:e014728.
   PubMed Web of Science ®Google Scholar
• Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279–1290.
   PubMed Web of Science ®Google Scholar
• Sørensen A-S, Kjær LK, Petersen KM, et al. The effect of smoking on the urinary excretion of 8-oxodG and 8-oxoGuo in patients with type 2 diabetes. Scand J Clin Lab Invest. 2017;77:253–258.
   PubMed Web of Science ®Google Scholar